Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors

NCT02428712 is registered in ClinicalTrials.gov with Fore Biotherapeutics as lead sponsor.

NCT NCT02428712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors
Lead sponsor
Fore Biotherapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2015
Completion date
July 12, 2024
Enrollment
113 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable solid tumors, braf-mutated tumors